BridgeBio Pharma (BBIO) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 285.3% versus a gain of 11.6%. Over five years, BBIO leads with a +92.2% price change compared with -42.0% for SYRE. BridgeBio Pharma is the larger company by market cap ($14.81 billion vs $8.88 billion), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | SYRE |
|---|---|---|
| Share price | $76.03 | $93.47 |
| Market cap | $14.81B | $8.88B |
| 1-day change | -2.75% | -4.26% |
| YTD return | -0.60% | +185.32% |
| 1-year return | +11.63% | +285.28% |
| 5-year return | +92.24% | -42.03% |
| EPS (TTM) | $-3.03 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $0 |
| Revenue growth (YoY) | +126.26% | — |
| Net income (latest FY) | $-732.94M | $-155.20M |
| Gross margin | 95.82% | — |
| Operating margin | -104.25% | — |
| Net margin | -145.98% | — |
| 52-week high | $93.42 | $110.64 |
| 52-week low | $62.50 | $24.58 |
| Distance from 52-week high | -18.61% | -15.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +40.73% | +32.52% |
| Average volume | 2.67M | 1.26M |
| Shares outstanding | 194.80M | 94.97M |
| Employees | 1,081 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed BBIO by 273.7 percentage points over the past year.
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
BBIO vs SYRE FAQ
Which is bigger, BridgeBio Pharma or Spyre Therapeutics?
BridgeBio Pharma (BBIO) is larger, with a market capitalization of $14.81B compared with $8.88B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, BBIO or SYRE?
SYRE returned +285.28% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.